Introduction
============

Testosterone (T) deficiency (TD; hypogonadism) is a well-established medical condition, which has been recognized for \>70 years. T therapy (TTh) has been long reported as an effective and safe treatment in patients with TD, and several studies have reported beneficial effects of TTh in patients with peripheral vascular disease and angina pectoris.[@b1-vhrm-12-251] Over the past several decades, a wealth of knowledge has accumulated regarding the negative impact of hypogonadism on men's overall health and quality of life.[@b2-vhrm-12-251] Furthermore, the deleterious effects of androgen deprivation therapy (ADT) in men with prostate cancer on cardiometabolic risk seem to be well established.[@b3-vhrm-12-251]

Despite the common belief that T may increase the incidence of coronary artery disease (CAD), the scientific evidence suggests that TD increases the likelihood and the degree of coronary atherosclerosis.[@b4-vhrm-12-251] Hypogonadism is associated with increased cardiometabolic risk and increased risk of all-cause and cardiovascular (CV) mortality,[@b1-vhrm-12-251],[@b4-vhrm-12-251]--[@b7-vhrm-12-251] while higher T levels were associated with lower incidence of sudden cardiac arrest.[@b8-vhrm-12-251]

Despite the wealth of knowledge in the field of TTh and CV health,[@b1-vhrm-12-251] a few studies have recently reported controversial outcomes.[@b9-vhrm-12-251]--[@b12-vhrm-12-251] However, in response to a petition to place a black box warning on T products, both the US Food and Drug Administration and the European Medicines Agency have evaluated the available evidence and concluded that there was no credible evidence that TTh contributes to increased cardiovascular disease (CVD) risk. More recent medium-term studies have refuted such claims.[@b13-vhrm-12-251]--[@b19-vhrm-12-251] To date, no long-term studies have assessed the effects of TTh in men with a history of CVD. Here, we report on the effects of long-term TTh in 77 men with TD and a history of CVD.

Patients and methods
====================

Patients
--------

From two prospective, cumulative observational registries of 622 unselected patients presenting to two urology clinics with hypogonadism (defined as T ≤12.1 nmol/L in the presence of symptoms), we identified 77 men (12.4% of all patients) with a history of CVD. In this subgroup, 77 men with a previous diagnosis of CAD (n=48) and/or a history of myocardial infarction (MI; n=40) and/or stroke (n=7) were analyzed. Mean age at baseline was 61±5 years and mean follow-up time 7.3±1.2 years (minimum: 4 years and maximum: 8 years). All 77 men were continuously treated with testosterone undecanoate (TU) injections (Nebido^®^; Bayer AG, Leverkusen, Germany) in 3-monthly intervals, following an initial interval of 6 weeks, for up to 8 years. Men were entered into the registry once they had received 1 year of treatment. Inclusion criteria were two separate morning measures of total testosterone ≤12.1 nmol/L and the presence of hypogonadal symptoms measured by the Aging Males' Symptoms scale (AMS). Exclusion criteria for T administration included previous treatment with androgens, prostate cancer, or any suspicion thereof, such as prostate-specific antigen levels \>4 ng/mL or abnormal findings upon digital rectal examination, International Prostate Symptom Score (IPSS) \>19 points, breast cancer, recent angina, or severe untreated sleep apnea.

Assessment and follow-up
------------------------

At each or each other visit, we measured the following parameters: total plasma T levels, weight, waist circumference (WC), body mass index (BMI), hemoglobin, hematocrit, fasting glucose levels, glycated hemoglobin (HbA~1c~), systolic blood pressure (SBP), diastolic blood pressure (DPB), heart rate, pulse pressure, lipid profile (total cholesterol \[TC\], low-density lipoprotein \[LDL\] cholesterol, high-density lipoprotein \[HDL\] cholesterol, triglycerides \[TGs\]), C-reactive protein, and liver transaminases. We also assessed prostate volume, prostate-specific antigen, and questionnaires IPSS, AMS, and International Index of Erectile Function, Erectile Function domain (IIEF-EF). Measures were taken between two and four times per year, and annual average was calculated. Ethical guidelines as formulated by the German "Ärztekammer" (the German Medical Association) for observational studies in patients receiving standard treatment were followed. According to these guidelines, no formal ethical approval is required for the evaluation of results obtained during standard treatment. After receiving an explanation regarding the nature and the purpose of the study, all subjects provided written consent to be included in the registry and have their data analyzed. Measurements of the parameters measured in this study were carried out as previously described.[@b20-vhrm-12-251],[@b21-vhrm-12-251]

Statistical analyses were described previously. Briefly, for continuous variables, mean, median, standard deviation, range, minimum, maximum, and sample size for the sample were reported at each time point. For categorical variables, the frequency distribution was reported. We tested the hypotheses regarding change in outcome scores across the study period by fitting a linear mixed-effects model to the data. Time (to indicate follow-up interviews) was included as a fixed effect in the model. A random effect was included in the model for the intercept. Estimation and test of change in scores were determined by computing the differences in least square means at baseline versus the score at each follow-up visit.[@b20-vhrm-12-251],[@b21-vhrm-12-251]

Results
=======

Baseline characteristics
------------------------

Baseline clinical characteristics of the 77 patients included in the long-term registry are described in [Table 1](#t1-vhrm-12-251){ref-type="table"}: mean age was 61±5 years (minimum: 43 and maximum: 68). Approximately 52% of the subjects had a previous MI, and 9% had a previous stroke. A previous diagnosis of CAD had been made in 62% of the subjects. In all, 53% had type 2 diabetes mellitus. Furthermore, 94% of the subjects were on antihypertensives, 75% on statins, and 48% on antidiabetic medications.

Effects of long-term TTh on weight loss, WC, and BMI
----------------------------------------------------

A marked and significant weight loss (WL) was observed after 8 years of continuous TTh in the 77 hypogonadal men receiving TTh ([Figure 1A](#f1-vhrm-12-251){ref-type="fig"}). WL was progressive and significant from year to year and amounted to 24 kg after 8 years. The percentage of change in weight over the follow-up period is shown in [Figure 1B](#f1-vhrm-12-251){ref-type="fig"}. Gradual and significant fractional change in weight is noted. The percentage of change was progressive and increased with continuous treatment and appeared more marked after the initial period (model adjusted 2.6% after 1 year, 7.1% after 2 years, 10.4% after 3 years, 13.2% after 4 years, 15.4% after 5 years, 17.4% after 6 years, 19.0% after 7 years, and 20.2% after 8 years). The gradual WL was accompanied by a marked and significant gradual decrease in WC ([Figure 1C](#f1-vhrm-12-251){ref-type="fig"}). The reduction in WC in response to TTh was significant from year to year and amounted to 13 cm at the end of the follow-up period of 8 years (model adjusted 1.7% after 1 year, 4.4% after 2 years, 6.3% after 3 years, 7.7% after 4 years, 8.8% after 5 years, 9.6% after 6 years, 10.4% after 7 years, and 11.1% after 8 years). The anthropometric data were also analyzed to determine the changes in BMI. As shown in [Figure 1D](#f1-vhrm-12-251){ref-type="fig"}, considerable and significant reduction in BMI was observed over the entire follow-up period with a mean reduction of 8 kg/m^2^.

Effects of long-term TTh on metabolic parameters
------------------------------------------------

### Effects on HbA~1c~

Over the course of treatment, a significant and sustained change in the levels of HbA~1c~ occurred: 7.6% at baseline, 7.2% after 1 year, 6.8% after 2 years, 6.6% after 3 years, 6.4% after 4 years, 6.2% after 5 years, 6.0% after 6 years, 5.9% after 7 years, and 5.7% after 8 years ([Figure 2](#f2-vhrm-12-251){ref-type="fig"}). By the end of follow-up period, a reduction in HbA~1c~ of 2.0% was recorded (*P*\<0.0001).

Long-term TTh resulted in decreased fasting glucose from 6.0±1.2 mmol/L to 5.2±0.4 mmol/L. The change from baseline was −0.9±0.1 mmol/L (*P*\<0.0001).

The TGs:HDL ratio, a surrogate marker of insulin resistance, decreased from 5.4±2 to 2.5±0.6 (*P*\<0.0001).

### Effects on lipid profiles

TTh resulted in gradual and consistent decrease in TC levels. The decrease was statistically significant as early as 12 months (*P*\<0.0001) and reached a plateau at 48 months (*P*\<0.01 vs 36 months, thereafter nonsignificant). TC decreased from 7.8±0.9 mmol/L to 4.8±0.2 mmol/L, LDL from 4.7±0.9 mmol/L to 3.0±0.7 mmol/L, and TGs from 3.4±0.7 mmol/L to 2.1±0.1 mmol/L. HDL increased from 1.6±0.5 mmol/L to 2±0.5 mmol/L. The TC:HDL ratio declined from 5.5±2.0 to 2.6±0.7. Non-HDL cholesterol decreased from 241±30 mg/dL to 108±21 mg/dL (*P*\<0.0001 for all).

### Effects on SBP and DBP

TTh produced marked and sustained gradual decrease in SBP from 164±14 mmHg to 133±9 mmHg representing a reduction of 33±1 mmHg (*P*\<0.0001; [Figure 3A](#f3-vhrm-12-251){ref-type="fig"}). The decrease was significant and gradual over the first 6 years and remained low over the entire course of the 8 years of treatment. Similar results were recorded with the DBP, which decreased from 99±11 mmHg to 77±5 mmHg representing a reduction of 24±1 mmHg (*P*\<0.0001; [Figure 3B](#f3-vhrm-12-251){ref-type="fig"}). Again, a marked decrease was noted over the first 6 years of treatment and then remained low over the entire 8 years of treatment.

### Effects on pulse pressure

As shown in [Figure 4](#f4-vhrm-12-251){ref-type="fig"}, long-term TTh in hypogonadal patients with a history of CVD resulted in marked and significant reduction in pulse pressure from 65±6 to 57±8. The reduction in pulse pressure was gradual and significant over the course of treatment versus baseline as well as compared to the previous year for the first 2 years, with a mean change in pulse pressure of 9±1 at the end of the follow-up period.

### Effects on heart rate and inflammation

Heart rate (bpm) decreased from 79±4 to 73±2. C-reactive protein (mg/dL) declined from 3.7±4.5 to 0.2±0.3 (*P*\<0.0001).

### Effects on liver enzymes

Both aspartate aminotransferase and alanine aminotransferase decreased significantly.

### Effects on quality of life

Questionnaires for general quality of life (AMS), voiding function (IPSS), and erectile function (IIEF-EF) improved significantly. [Table 2](#t2-vhrm-12-251){ref-type="table"} summarizes the findings of this study with regard to the changes in metabolic parameters and quality of life in men with history of CVD.

Safety and compliance
---------------------

No patient had a major adverse CV event. No patient had a urological event (prostate cancer or voiding dysfunction). No patient missed a single injection. No patient dropped out.

Discussion
==========

In this observational registry study, we followed up 77 men with hypogonadism and a history of CVD on continuous TTh for up to 8 years. Here, we show that in this subset of patients, TTh was associated with reduced body weight, WC, and BMI. The gradual and marked decrease in body weight and WC are of importance since metabolic syndrome (MetS) and obesity are recognized as risk factors for CVD and reduction in weight of this magnitude is meaningful for reducing CVD risk. It is not surprising to observe the gradual, progressive, and sustained WL over the course of 8 years of treatment, since TTh was shown to reduce fat mass and increase lean body mass in men with hypogonadism.[@b1-vhrm-12-251] However, what was unexpected is that these patients with a diagnosis of a life-threatening disease had not been successful in managing their weight via other strategies. Their baseline BMI was 37 kg/m^2^, and only one patient was in the normal weight category at baseline, five patients were overweight, and 71 (92%) obese. More importantly, after 8 years of continuous TTh, we did not observe any increase in the classical CVD risk markers in this subset of patients,suggesting that this treatment does not increase the risk of CVD. The WL was associated with marked reductions in WC, suggesting that TTh ameliorates MetS components and may contribute to reduction in visceral fat, as described previously.[@b20-vhrm-12-251],[@b21-vhrm-12-251]

We and others have reported that TTh produces positive effects on blood pressure, glucose levels, insulin sensitivity, HbA~1c~ levels, and MetS components.[@b19-vhrm-12-251]--[@b27-vhrm-12-251] Diabetes is a major risk factor for CVD, and the majority of patients in this study were diabetics receiving standard treatment but with limited success according to their baseline HbA~1c~ levels of 7.6%. Our findings corroborate previous reports that TTh ameliorates hyperglycemia and insulin resistance, which are sustained for a period of 8 years. This is of critical importance, because diabetes is a chronic, progressive disease, and TTh seems to successfully control it.

In this study, we also report on a remarkable decrease in the levels of TC, LDL, and TGs with notable increase in HDL levels. We must note that despite most of the patients being treated with statins to control their dyslipidemia, most patients exhibited high levels of TC, LDL, and TGs at baseline. Our findings are consistent with data from other studies, which reported that long-term TTh in men with TD is associated with reduced levels of TC, LDL, and TGs coupled with beneficial increase in HDL.[@b20-vhrm-12-251]--[@b22-vhrm-12-251],[@b25-vhrm-12-251]--[@b27-vhrm-12-251] Such reductions in LDL and TGs and increased HDL have important implications in reducing CVD risk.[@b20-vhrm-12-251]--[@b22-vhrm-12-251] Furthermore, we noted a lower TC:HDL ratio. Since TC:HDL ratio is thought to predict the risk of CVD, in particular, ischemic heart disease, such reduction suggests improvements in the overall lipid profile and potential reduction in CVD risk. It should be emphasized that findings from studies on ADT in patients with advanced prostate cancer consistently reported an increase in TC, TGs, and LDL, suggesting that ADT (ie, intentionally induced hypogonadism) produces undesirable lipid profile and increases the risk of CVD.[@b2-vhrm-12-251],[@b3-vhrm-12-251] Thus, we believe that TTh confers favorable improvement in cardiometabolic function and reduces the risk of CVD.

It has been suggested that T modulates arterial blood pressure through various mechanisms, and TD may contribute to hypertension.[@b28-vhrm-12-251] Interestingly, men treated with ADT for prostate cancer showed markedly increased arterial stiffness.[@b29-vhrm-12-251] Svartberg et al[@b28-vhrm-12-251] reported that SBP was inversely associated with T levels, suggesting that hypogonadism contributes to higher blood pressure and TTh may reduce blood pressure.[@b20-vhrm-12-251],[@b21-vhrm-12-251],[@b28-vhrm-12-251] In this study, we report a significant and gradual decrease in blood pressure in response to TTh, which remained low over the entire course of the 8 years of TTh. We should emphasize that patients in this study were on anti-hypertensive drugs to control their blood pressure, yet they exhibited elevated blood pressure at baseline prior to TTh. Indeed, it has been suggested that TD may be a risk factor for hypertension, and TTh may ameliorate this parameter.[@b19-vhrm-12-251] As shown in [Figure 3](#f3-vhrm-12-251){ref-type="fig"}, TTh had a profound effect on blood pressure in this subset of patients with prior history of CVD.

The fact that the majority of patients were on concomitant medications (antihypertensives, lipid-lowering drugs, and antidiabetic medications) with limited success raises the question of medication adherence, which is known to be low in chronic diseases. Whether the effects of TTh are attributed solely to the physiological activity of T or augmentation of the medications for hypertension, diabetes, and dyslipidemia by administration of testosterone remains unknown. Injections of TU are invariably administered in the doctor's office so that a 100% adherence to TTh is guaranteed.

Our finding that pulse pressure, a surrogate marker for arterial stiffness, was significantly reduced is supported by data from a recent placebo-controlled study in which reduction in arterial stiffness was reported, following TTh. TTh has been shown to decrease arterial stiffness and respiratory quotient compared with placebo. TTh in men with hypogonadism reduced CVD risk factors with concomitant improvement in insulin sensitivity and glycemic control, even in studies of short duration.[@b27-vhrm-12-251] It should be noted that pulse pressure is considered a marker of vascular stiffness, and any reduction in this parameter is considered favorable for reducing CVD risk.[@b30-vhrm-12-251]

Although epidemiological studies have suggested that reduced T levels are associated with greater CVD risk,[@b31-vhrm-12-251] the use of TTh to treat hypogonadism remains controversial. In light of the fact that a marked decrease in visceral fat mass, increased lean body mass, and reduced circulating inflammatory cytokines, concomitant with improvement in endothelial cell function, have been reported,[@b24-vhrm-12-251] it would be expected that TTh may reduce the risk of CVD. Since T regulates a host of physiological and metabolic functions in liver, adipose tissue, muscles, coronary arteries, and the heart, it is not surprising that TTh reduces the risk of CVD.

Mortality in men with TD was reduced subsequent to TTh.[@b32-vhrm-12-251],[@b33-vhrm-12-251] Shores et al[@b32-vhrm-12-251] demonstrated that mortality in T-treated men was 10.3% compared with 20.7% in untreated hypogonadal men (*P*\<0.0001). Muraleedharan et al[@b33-vhrm-12-251] demonstrated, in hypogonadal men with type 2 diabetes mellitus, reduced mortality of 8.4% in men receiving TTh compared with 19.2% in untreated men. These findings are consistent with several studies summarized by Morgentaler et al.[@b1-vhrm-12-251] CV benefits of TTh have been shown in interventional studies, including benefits in men with congestive heart failure, cardiac ischemia/angina, including a reduction in carotid intima--media thickness.[@b1-vhrm-12-251] Most studies identified an inverse association between serum T concentration and all-cause or CV mortality.

Recently, Corona et al[@b34-vhrm-12-251] analyzed a large number of published studies for the benefits and risks of TTh and concluded that there was no evidence of increased CV risk with TTh but protective effects in men with metabolic disorders and suggested that TTh has benefits on cardiometabolic function. The well-recognized benefits of TTh in men with hypogonadism are the improvement in sexual desire and erectile function,[@b34-vhrm-12-251],[@b35-vhrm-12-251] increased energy, mood, and vitality,[@b35-vhrm-12-251]--[@b39-vhrm-12-251] increased lean body mass,[@b37-vhrm-12-251],[@b38-vhrm-12-251] reduction in total body fat mass,[@b37-vhrm-12-251],[@b38-vhrm-12-251] and reduction in WC.[@b20-vhrm-12-251],[@b21-vhrm-12-251],[@b25-vhrm-12-251]

It must be emphasized that several recent studies[@b13-vhrm-12-251]--[@b18-vhrm-12-251] showed reduced incidence of MI, stroke and mortality in men treated with T, achieving physiological T levels. The study by Sharma et al[@b15-vhrm-12-251] clearly showed the deficit of other studies in which incomplete restoration of physiological levels of T was not accounted for, and when such information was not taken into consideration, the CVD risks reported cannot be taken seriously since they were not substantiated by evidence. The prospective controlled study by Morgunov et al[@b39-vhrm-12-251] showed that stroke patients treated with TU injections for 2 years starting 1 week after stroke occurrence had a significantly reduced incidence of recurrent stroke of 7.1% in the testosterone group compared to 16.6% in the untreated control group.[@b39-vhrm-12-251]

It has been fiercely argued that most of the data presented in the aforementioned studies represent retrospective observational analyses or registry studies. We recognize that randomized controlled clinical trials are considered to be the gold standard for assessing the efficacy and safety of a given therapy. However, the costs associated with such trials recruiting 6,000 to 8,000 men with hypogonadism and treatment and follow-up for 5--10 years are astronomical, and no governmental agency or pharmaceutical industry would wish to incur such costs. Evidence-based medicine should be based on data reported from randomized, placebo-controlled trials as well as from prospective or retrospective observational studies, registries, case control studies, and meta-analyses to glean all the critical information. Therefore, it is imperative that we utilize all available data irrespective of the nature of the study to extract relevant information on TTh to advance our knowledge of the benefits and risks of TTh.

It has been strongly suggested that observational and registry studies are a useful source of real-life data that provide valuable clinical information that augments and complements data from other types of studies, including randomized controlled trials. Observational studies provide relevant information on the benefit and risks to patients in routine clinical practice.[@b40-vhrm-12-251] Of course, we must keep in mind that similar to all other studies, observational studies have their own unique limitations, which should be carefully considered in the assessment of risk and treatment benefit.[@b40-vhrm-12-251] The scientific and clinical community appreciates the fact that data from observational studies may not provide complete or adequate information to separate the effects of a new treatment from other factors. Nevertheless, observational studies are considered representative of the daily routine clinical practices that are encountered in the general population and provide critical information on the long-term safety and effectiveness in clinical practice, especially relevant information regarding adherence and health outcomes in the general population.[@b40-vhrm-12-251]

Study limitations
-----------------

The present study was not designed or powered to address the effects of TTh in men with existing CVD. There was no adjudication of previous CV events that were reported by the patients as part of their anamnesis. Since patients were treated for their underlying diseases by other specialists than the urologists performing TTh, there was no precise monitoring of concomitant medications so that changes in medication cannot be excluded. There was no control group.

Conclusion
==========

Long-term TTh in men with hypogonadism and a history of CVD appears to be an effective approach to achieve sustained improvements in anthropometric parameters and cardiometabolic function, with no reported increases in CVD events. The fact that none of these high-risk patients had another CV event may suggest that TTh can have beneficial effects in men with a history of CVD, provided comprehensive secondary prevention therapy is already in place.
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###### 

Anthropometric parameters in hypogonadal men with a history of cardiovascular disease receiving long-term testosterone therapy.

**Notes:** (**A**) Body weight (kg), (**B**) weight loss (%), (**C**) waist circumference (cm), and (**D**) BMI (kg/m^2^). Data are shown as mean ± SE.

**Abbreviations:** BMI, body mass index; SE, standard error.
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![HbA~1c~ (%) in hypogonadal men with a history of cardiovascular disease receiving long-term testosterone therapy.\
**Note:** Data are shown as mean ± SE.\
**Abbreviations:** HbA~1c~, glycated hemoglobin; SE, standard error.](vhrm-12-251Fig2){#f2-vhrm-12-251}

![Blood pressure (mmHg) in hypogonadal men with a history of cardiovascular disease receiving long-term testosterone therapy.\
**Notes:** (**A**) Systolic blood pressure and (**B**) diastolic blood pressure. Data are shown as mean ± SE.\
**Abbreviations:** SE, standard error; NS, nonsignificant.](vhrm-12-251Fig3){#f3-vhrm-12-251}

![Pulse pressure in hypogonadal men with a history of cardiovascular disease receiving long-term testosterone therapy.\
**Notes:** Data are shown as mean ± SE.\
**Abbreviations:** SE, standard error; NS, nonsignificant.](vhrm-12-251Fig4){#f4-vhrm-12-251}

###### 

Baseline comorbidities and concomitant medication in 77 hypogonadal men with a history of cardiovascular diseases

  ----------------------------------------------- ---------------------
  Age (minimum; maximum) (years)                  60.65±4.98 (43; 68)
  Metabolic diseases                              
  Obesity                                         71 (92.2%)
  Overweight                                      5 (6.5%)
  Diabetes mellitus type 2                        41 (53.2%)
  Diabetes mellitus type 1                        5 (6.5%)
  Cardiovascular diseases                         
  History of myocardial infarction                40 (51.9%)
  History of stroke                               7 (9.1%)
  Previous diagnosis of coronary artery disease   48 (62.3%)
  Total cardiovascular diseases                   77 (100%)
  Medication use                                  
  Antihypertensives                               72 (93.5%)
  Lipid-lowering medications                      58 (75.3%)
  Antidiabetic medications                        37 (48.1%)
  ----------------------------------------------- ---------------------

###### 

Changes following testosterone therapy in anthropometric, metabolic, and quality of life parameters in hypogonadal men with a history of cardiovascular diseases

                                All CVD patients (n=77)                                           
  ----------------------------- ------------------------- ------ ------ ----------- ------ ------ -------------------------------------------------------
  Anthropometry                                                                                   
  Weight (kg)                   114±13                    72     139    91±9        74     110    −24±1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  BMI (kg/m^2^)                 37±4                      25     46     29±3        25     35     −8±0[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Weight change (%)             0                         0      0      −19.6±5.7   3.1    −29    −20.2±0.5[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Waist circumference (cm)      112±8                     88     129    99±6        84     114    −13±0.3[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Waist:height ratio            0.64±0.05                 0.51   0.73   0.56±0.04   0.49   0.64   −0.07±0[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Testosterone                                                                                    
  Testosterone (nmol/L)         9.8±1.6                   4.8    11.8   16.8±1.9    14.7   23.8   6.9±0.3[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Prostate parameters                                                                             
  Prostate volume (mL)          34±10                     16     56     36±10       17     57     2.5±0.2[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  PSA (ng/mL)                   2.0±1.0                   0.1    3.9    2.2±0.8     0.8    3.5    0.2±0.0[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  IPSS                          9±4                       1      19     3±2         1      10     −7±0.3[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Erectile function                                                                               
  IIEF-EF                       20±6                      3      27     25±5        12     29     6±0.4[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Quality of life                                                                                 
  AMS                           57±9                      36     73     19±4        17     30     −39±1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Glycemic control                                                                                
  Fasting glucose (mmol/L)      6.0±1.2                   3.7    12.7   5.2±0.4     4.0    6.6    −0.9±0.1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  HbA~1c~ (%)                   7.6±1.2                   5.1    9.4    5.7±0.4     5.0    6.6    −2.0±0.1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Triglycerides:HDL ratio       5.4±2                     2.0    11.3   2.5±0.6     1.6    4.0    −3.1±0.1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Lipids                                                                                          
  Total cholesterol (mmol/L)    7.8±0.9                   5.7    10.1   4.8±0.2     4.3    5.3    −3±0.1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  HDL (mmol/L)                  1.6±0.5                   0.7    2.3    2±0.5       1.2    3.1    0.6±0.0[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  LDL (mmol/L)                  4.7±0.9                   2.0    7.2    3.0±0.7     1.1    4.1    −1.6±0.1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Triglycerides (mmol/L)        3.4±0.7                   1.4    5      2.1±0.1     1.8    2.4    −1.3±0.1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Total cholesterol:HDL ratio   5.5±2                     3.5    12.9   2.6±0.7     1.6    4.1    −3.2±0.1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Non-HDL cholesterol (mg/dL)   241±30                    163    332    108±21      68     152    −136±3[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Erythropoiesis/blood count                                                                      
  Hemoglobin (g/dL)             14.4±0.7                  12.1   15.5   15.0±0.5    13.8   15.8   0.7±0.1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Hematocrit (%)                43.2±3.1                  33     50     48.1±1.6    43.5   51     5.0±0.3[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Leukocytes (10^9^/L)          7.1±2.2                   4.3    19.8   6.5±0.5     5.5    7.5    −0.6±0.2[\#](#tfn2-vhrm-12-251){ref-type="table-fn"}
  Liver transaminases                                                                             
  AST (U/L)                     40.7±14.7                 19     87     17.4±4.2    12.3   32.5   −23.8±1.2[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  ALT (U/L)                     41.5±17.1                 19     100    17.4±4.8    9.8    30     −24.9±1.5[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  AST:ALT ratio                 1.0±0.2                   0.7    1.4    1.0±0.1     0.8    1.3    0.0±0.0
  Inflammation                                                                                    
  CRP (mg/dL)                   3.7±4.5                   0.1    24.7   0.2±0.3     0.1    1.3    −3.6±0.3[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Blood pressure                                                                                  
  Systolic (mmHg)               164±14                    125    189    133±9       117    152    −33±1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Diastolic (mmHg)              99±11                     70     119    77±5        70     89     −24±1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Pulse pressure                65±6                      49     82     57±8        34     69     −9±1[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}
  Heart rate (bpm)              79±4                      72     88     73±2        68     81     −6±0[\*](#tfn1-vhrm-12-251){ref-type="table-fn"}

**Notes:**

*P*\<0.0001 vs baseline.

*P*\<0.01.

**Abbreviations:** CVD, cardiovascular disease; SD, standard deviation; SE, standard error; BMI, body mass index; PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score; IIEF-EF, International Index of Erectile Function, Erectile Function domain; AMS, Aging Males' Symptoms scale; HbA~1c~, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP, C-reactive protein.
